National Center for Advancing Translational Sciences Notice of Closed Meeting, 43247-43248 [2020-15375]

Download as PDF 43247 Federal Register / Vol. 85, No. 137 / Thursday, July 16, 2020 / Notices comments relating to the contemplated an exclusive patent license should be directed to: Michael Shmilovich, Esq., Senior Licensing and Patent Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479, phone number 301–435–5019, or shmilovm@ mail.nih.gov. SUPPLEMENTARY INFORMATION: INTELLECTUAL PROPERTY NIH ref No. E–284–2012–0–US–01 ..... E–284–2012–1–US–01 ..... E–284–2012–2–PCT–01 ... E–284–2012–2–AU–02 ..... E–284–2012–2–CA–03 ..... E–284–2012–2–JP–04 ...... E–284–2012–2–US–05 ..... E–284–2012–2–US–07 ..... E–284–2012–2–EP–06 ..... E–284–2012–2–PCT–08 ... E–164–2018–0–US–01 ..... E–164–2018–1–US–01 ..... E–164–2018–2–US–01 ..... E–164–2018–3–PCT–01 ... Methods And Compositions For Treating Genetically Linked Diseases Of The Eye. Methods And Compositions For Treating Genetically Linked Diseases Of The Eye. Methods And Compositions For Treating Genetically Linked Diseases Of The Eye. AAV8 retinoschisin expression vector for treating X-linked retinoschisis. AAV8 retinoschisin expression vector for treating X-linked retinoschisis. Methods And Compositions For Treating Genetically Linked Diseases Of The Eye. Methods And Compositions For Treating Genetically Linked Diseases Of The Eye. Methods And Compositions For Treating Genetically Linked Diseases Of The Eye. Methods And Compositions For Treating Genetically Linked Diseases Of The Eye. Methods And Compositions For Treating Genetically Linked Diseases Of The Eye. Intraocular Delivery Of Gene Therapy Expression Vectors. Intraocular Delivery Of Gene Therapy Expression Vectors. Intraocular Delivery Of Gene Therapy Expression Vectors. Intraocular Delivery Of Gene Therapy Expression Vectors. All U.S. and foreign patents and applications claiming priority to any member of the above. The patent rights in these inventions have been assigned or exclusively licensed to the Government of the United States of America. The prospective exclusive license territory may be worldwide and in fields of use that may be limited to human therapeutics for (1) X-linked juvenile retinoschisis and (2) schisis cavity associated ocular disease or injury. The aforementioned patent estates cover inventions directed to gene therapy and specifically, expression vectors and therapeutic methods of using such vectors in the treatment of ocular diseases resulting from failure to produce or the defective production of an ocular protein. This invention is also directed to methods of administering expression vectors capable of modulating a target gene or gene product for the treatment of ocular disease. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Heart, Lung, and Blood Institute receives written evidence and argument that establishes that the grant of the VerDate Sep<11>2014 Patent application No. Title 17:43 Jul 15, 2020 Jkt 250001 February 15, 2013. 61/815,636 ................. April 24, 2013. PCT/US2014/16389 .. February 14, 2014. 2014216160 ............... February 14, 2014 ..... 2014216160 July 13, 2017. 2900231 ..................... February 14, 2014 ..... 2900231 July 30, 2019. 2015–558144 ............. February 14, 2014 ..... 6449175 December 14, 2018. 14/766,842 ................. February 14, 2014 ..... 9,873,893 15/876,821 ................. February 14, 2014 ..... 10,350,306 14708176.4 ................ February 14, 2014. PCT/US2019/14418 .. January 21, 2019. 62/701,267 ................. July 20, 2018. 62/724,480 ................. August 29, 2018. 62/768,590 ................. November 16, 2019. PCT/US2019/042365 July 18, 2019. Dated: July 2, 2020. Michael Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute. [FR Doc. 2020–15340 Filed 7–15–20; 8:45 am] BILLING CODE 4140–01–P Frm 00043 Issue date 61/765,654 ................. license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. In response to this notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552. PO 00000 Issued patent No. Filing date Fmt 4703 Sfmt 4703 January 23, 2018. July 16, 2019. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Advancing Translational Sciences Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; NTU Bench Testing. Date: August 12, 2020. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1078, Bethesda, MD 20892 (Virtual Meeting). E:\FR\FM\16JYN1.SGM 16JYN1 43248 Federal Register / Vol. 85, No. 137 / Thursday, July 16, 2020 / Notices Contact Person: Rahat (Rani) Khan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1078, Bethesda, MD 20892, 301–594–7319, khanr2@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS) Dated: July 13, 2020. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–15375 Filed 7–15–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; SARS– COV–2 Serological Sciences Centers of Excellence. Date: August 17–18, 2020. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W530, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Shamala K. Srinivas, Ph.D., Associate Director, Office of Referral, Review, and Program Coordination, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W530, Rockville, MD 20850, 240– 276–6442, ss537t@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; K22 Transition Career Development Award. Date: September 22, 2020. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. VerDate Sep<11>2014 17:43 Jul 15, 2020 Jkt 250001 Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W234, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, 7W234, Rockville, MD 20850, 240–276–6368, stoicaa2@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI SPORE (P50) I Review. Date: September 22–23, 2020. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W244, Rockville, MD 20850 (Telephone Conference Call). Contact Person: John Paul Cairns, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W244, Rockville, MD 20892, 240–276–5415 paul.cairns@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI SPORE (P50) II Review. Date: September 23–24, 2020. Time: 10:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W116, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Klaus B. Piontek, Ph.D., Scientific Review Officer,Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W116Rockville, MD 20850, 240–276–5413 klaus.piontek@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project I (PO1). Date: September 24–25, 2020. Time: 9:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W618, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Mukesh Kumar, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W618, Rockville, MD 20850, 240–276–6611 mukesh.kumar3@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI SPORE (P50) III Review. Date: September 24–25, 2020. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W122, Rockville, MD 20850 (Telephone Conference Call). PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 Contact Person: Anita T. Tandle, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W122, Rockville, MD 20850, 240–276–5085, tandlea@mail.nih.gov. Name of Committee: National Cancer Institute Initial Review Group; Subcommittee J—Career Development. Date: October 15–16, 2020. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: NCI Shady Grove, 9609 Medical Center Drive, Room 7W624, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Tushar Deb, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W624, Rockville, MD 20850, 240– 276–6132, tushar.deb@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project (P01) Review Meeting II. Date: October 15–16, 2020. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W120, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Majed M. Hamawy, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W120, Rockville, MD 20850, 240–276–6457, mh101v@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project III (P01). Date: October 20–21, 2020. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W634, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Michael E. Lindquist, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W634, Rockville, MD 20850, 240– 276–5735, mike.lindquist@nih.gov. Name of Committee: National Cancer Institute Initial Review Group; Subcommittee I—Transition to Independence. Date: October 21–22, 2020. Time: 11:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W602, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Delia Tang, M.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer E:\FR\FM\16JYN1.SGM 16JYN1

Agencies

[Federal Register Volume 85, Number 137 (Thursday, July 16, 2020)]
[Notices]
[Pages 43247-43248]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-15375]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Advancing Translational Sciences Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Advancing Translational 
Sciences Special Emphasis Panel; NTU Bench Testing.
    Date: August 12, 2020.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Center for Advancing Translational Sciences, 
National Institutes of Health, 6701 Democracy Boulevard, Room 1078, 
Bethesda, MD 20892 (Virtual Meeting).

[[Page 43248]]

    Contact Person: Rahat (Rani) Khan, Ph.D., Scientific Review 
Officer, Office of Scientific Review, National Center for Advancing 
Translational Sciences, National Institutes of Health, 6701 
Democracy Boulevard, Room 1078, Bethesda, MD 20892, 301-594-7319, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, 
Pharmacology, Physiology, and Biological Chemistry Research; 93.350, 
B--Cooperative Agreements; 93.859, Biomedical Research and Research 
Training, National Institutes of Health, HHS)

    Dated: July 13, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-15375 Filed 7-15-20; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.